Brief: VolitionRX Cash And Cash Equivalents As Of March 31 Totaled $16.2 Mln
May 8 (Reuters) - VolitionRX Ltd VNRX.A :
* VOLITIONRX LIMITED ANNOUNCES FIRST QUARTER 2019 FINANCIAL
RESULTS AND BUSINESS UPDATE
* VOLITIONRX LTD - CASH AND CASH EQUIVALENTS AS OF MARCH 31,
2019
TOTALED $16.2 MILLION COMPARED TO $13.4 MILLION AS OF END OF
2018
* VOLITIONRX LTD - CONTINUE TO MANAGE CASH CAREFULLY WITH A
CASH
BURN OF $3.9 MILLION IN Q1 OF 2019
Source text for Eikon: ID:nPnb10bzTa
Further company coverage: VNRX.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on VolitionRX
See all newsBrief: Volitionrx -Files Preliminary Prospectus For 10,006,360 Shares Of Common Stock Offered By Selling Stockholder - SEC Filing
Brief: Volitionrx - Advances Nu.Q Nets Platform Towards Commercialization
Brief: VolitionRX Limited Announces First Quarter 2026 Financial Results
Brief: Volition Reports Breakthrough In Liquid Biopsy Achievement Of Over 99% Purity In Isolating Cancer Dna
Brief: Volition Announces First Ever Automated Nu.Q® Vet Cancer Test With Fujifilm Vet Systems